Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Rheumatoid arthritis

Are ACPA-positive and ACPA-negative RA the same disease?

Seemingly contrasting genetic backgrounds in anti-citrullinated-protein antibody (ACPA)-positive and ACPA-negative rheumatoid arthritis (RA) support the notion that these are in fact two distinct disease subsets, with different underlying pathogenesis, that might need tailored treatment strategies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Syversen, S. W. et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann. Rheum. Dis. 67, 212–217 (2008).

    Article  CAS  Google Scholar 

  2. Padyukov, L. et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259–265 (2011).

    Article  Google Scholar 

  3. Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508–514 (2010).

    Article  CAS  Google Scholar 

  4. Huizinga, T. W. et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52, 3433–3438 (2005).

    Article  CAS  Google Scholar 

  5. Verpoort, K. N. et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 52, 3058–3062 (2005).

    Article  CAS  Google Scholar 

  6. Daha, N. A. et al. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 60, 1255–1260 (2009).

    Article  Google Scholar 

  7. Uysal, H. et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206, 449–462 (2009).

    Article  CAS  Google Scholar 

  8. Schuerwegh, A. J. et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 107, 2586–2591 (2010).

    Article  CAS  Google Scholar 

  9. van Dongen, H. et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424–1432 (2007).

    Article  CAS  Google Scholar 

  10. Sellam, J. et al. B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.30233.

Download references


The authors' work is supported by grants from the Dutch Arthritis Foundation and the European Union (Sixth Framework Program integrated project Autocure and Seventh Framework Program integrated project Masterswitch number 223404).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Nina A. Daha.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Daha, N., Toes, R. Are ACPA-positive and ACPA-negative RA the same disease?. Nat Rev Rheumatol 7, 202–203 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing